Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Sees Large Decline in Short Interest
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Sees Large Decline in Short Interest
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 7,460,000 shares, a decrease of 5.1% from the August 31st total of 7,860,000 shares. Based on an average trading volume of 891,900 shares, the short-interest ratio is presently 8.4 days. Approximately 15.9% of the shares of the company are short sold.
纳斯达克(Deciphera PharmPharmticals，Inc.)(DCPH-GET评级)是空头股数9月份大幅下跌的目标。截至9月15日，空头股数共有746万股，比8月31日的786万股减少了5.1%。以平均成交量891,900股计算，目前短息比率为8.4天。该公司约15.9%的股份被卖空。
Hedge Funds Weigh In On Deciphera Pharmaceuticals
对冲基金参与Deciphera PharmPharmticals
Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in shares of Deciphera Pharmaceuticals by 739.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,635,510 shares of the company's stock worth $35,519,000 after purchasing an additional 3,202,527 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at about $10,772,000. Federated Hermes Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 125.5% in the first quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company's stock valued at $18,161,000 after purchasing an additional 1,090,368 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 27.6% in the first quarter. BlackRock Inc. now owns 4,845,376 shares of the company's stock valued at $44,917,000 after purchasing an additional 1,047,807 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in shares of Deciphera Pharmaceuticals by 12.0% in the second quarter. Deerfield Management Company L.P. Series C now owns 6,250,964 shares of the company's stock valued at $82,200,000 after purchasing an additional 670,508 shares in the last quarter. Institutional investors own 72.29% of the company's stock.
机构投资者最近买卖了该公司的股票。去年第四季度，高盛在Deciphera PharmPharmticals的持股增加了739.6%。高盛股份有限公司在此期间增持了3,202,527股，目前持有该公司3,635,510股股票，价值35,519,000美元。加拿大养老金计划投资委员会在第四季度购买了Deciphera制药公司的新股份，价值约10,772,000美元。联合爱马仕公司在第一季度增持了125.5%的Deciphera PharmPharmticals股票。联合爱马仕公司目前持有1,959,078股该公司股票，价值18,161,000美元，上一季度又购买了1,090,368股。今年第一季度，贝莱德增持了Deciphera PharmPharmticals的股份，增持幅度为27.6%。贝莱德股份有限公司在上个季度购买了1,047,807股后，目前持有该公司4,845,376股股票，价值44,917,000美元。最后，Deerfield Management Company L.P.Series C在第二季度增持了Deciphera PharmPharmticals的股票12.0%。Deerfield Management Company L.P.C系列现在拥有该公司6,250,964股股票，价值82,200,000美元，上个季度又购买了670,508股。机构投资者持有该公司72.29%的股票。
Analyst Upgrades and Downgrades
分析师升级和下调评级
DCPH has been the topic of several analyst reports. Piper Sandler increased their target price on Deciphera Pharmaceuticals from $13.00 to $18.00 in a research report on Sunday, September 11th. JMP Securities raised Deciphera Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $23.00 target price for the company in a research note on Friday, August 5th. Cowen started coverage on Deciphera Pharmaceuticals in a research note on Monday, August 29th. They set an "outperform" rating and a $25.00 target price for the company. SVB Leerink upped their target price on Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Monday, September 12th. Finally, Stifel Nicolaus upped their target price on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the company a "hold" rating in a report on Tuesday, September 27th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. According to MarketBeat, Deciphera Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $18.70.
DCPH一直是几份分析师报告的主题。派珀·桑德勒在9月11日周日的一份研究报告中将Deciphera PharmPharmticals的目标价从13.00美元上调至18.00美元。JMP Securities在8月5日(周五)的一份研究报告中将Deciphera PharmPharmticals的评级从“市场表现”上调至“表现优于大盘”，并为该公司设定了2300美元的目标价。考恩在8月29日星期一的一份研究报告中开始报道Deciphera制药公司。他们为该公司设定了“跑赢大盘”的评级和25.00美元的目标价。SVB Leerink在9月12日周一的一份报告中将Deciphera PharmPharmticals的目标价从21.00美元上调至25.00美元，并给予该公司“跑赢大盘”的评级。最后，Stifel Nicolaus在9月27日周二的一份报告中将Deciphera PharmPharmticals的目标价从11.00美元上调至18.00美元，并给予该公司“持有”评级。两名股票研究分析师对该股的评级为卖出，五名分析师给予该公司持有评级，五名分析师给予该公司买入评级。根据MarketBeat，Deciphera PharmPharmticals目前的共识评级为持有，平均目标价为18.70美元。
Deciphera Pharmaceuticals Stock Up 5.0 %
Deciphera制药类股上涨5.0%
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.05. The company had revenue of $32.49 million for the quarter, compared to analyst estimates of $30.11 million. Deciphera Pharmaceuticals had a negative return on equity of 74.37% and a negative net margin of 231.99%. Deciphera Pharmaceuticals's revenue for the quarter was up 37.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.21) EPS. As a group, analysts anticipate that Deciphera Pharmaceuticals will post -2.5 earnings per share for the current year.
Deciphera制药(纳斯达克：DCPH-GET评级)最近一次公布季度收益数据是在8月4日星期四。该公司公布本季度每股收益(0.60美元)，比普遍预期的(0.65美元)高出0.05美元。该公司本季度营收为3,249万美元，而分析师预期为3,011万美元。Deciphera制药公司的净资产回报率为负74.37%，净利润率为负231.99%。与去年同期相比，Deciphera制药公司本季度的收入增长了37.8%。去年同期，该公司每股收益为1.21美元。作为一个整体，分析师预计Deciphera制药公司本年度的每股收益将为2.5%。
About Deciphera Pharmaceuticals
关于Deciphera制药公司
(Get Rating)
(获取评级)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
生物制药公司Deciphera PharmPharmticals，Inc.通过解决美国和国际上限制对现有癌症疗法反应的速度和持久性的关键耐药机制，开发改善癌症患者生命的药物。它的主要候选药物是用于治疗胃肠道间质瘤(GIST)的QINLOCK，以及用于治疗二线GIST的3期试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免费获取StockNews.com关于Deciphera制药的研究报告(DCPH)
- 阿彻·丹尼尔斯·米德兰：49年增长的红利英雄
- 全自动拖拉机会让迪尔成为农业领域的特斯拉吗？
- 麦格纳国际是您的汽车和电动汽车一站式库存
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Deciphera PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Deciphera制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。